Stem Cells Market to Reach US$ 32.57 Bn by 2031, Growing at 11.5% CAGR: Wissen Research

Wissen Research forecasts the global stem-cells market will grow from $18.9 billion in 2026 to $32.57 billion by 2031, a 11.5% CAGR, supported by regenerative medicine demand, cell-therapy manufacturing advances and drug-discovery applications. Adult stem cells accounted for about 72% of 2025 revenue and scalable allogeneic therapies held roughly 60%, while North America led with nearly 44% market share and Asia-Pacific is projected to grow fastest. Recent activity includes MEDIPOST raising about $140 million for late-stage trials and manufacturing expansion, alongside partnerships involving Applied StemCell, Cellipont Bioservices, Aspect Biosystems and Novo Nordisk.

Analysis

This is more supportive of the cell-therapy picks-and-shovels complex than of therapeutic developers. Commercial adoption hinges on batch reproducibility, release testing, closed-system processing, cold-chain logistics, and regulatory-grade documentation; these are recurring consumables and service revenues with lower binary clinical risk. TMO, DHR, TECH, SRT3, and LONN have asymmetric exposure to a rise in development programs because they monetize activity before product approval, while GLW benefits only if higher-throughput cell culture translates into incremental demand for specialized labware.

The critical competitive variable is whether allogeneic programs actually achieve durable efficacy without immunogenicity or safety setbacks. If they do, centralized manufacturing favors scaled CDMOs and integrated workflow vendors, likely concentrating share with Lonza and Thermo Fisher rather than smaller reagent specialists. Conversely, continued preference for autologous programs would raise per-patient processing intensity but constrain margins, capacity utilization, and payer adoption—bad for the broad commercial-volume narrative despite higher nominal lab spend.

Near term, this press-release-level market forecast is not a standalone catalyst and should not move estimates. Over 1-3 months, watch bookings, bioprocess segment orders, and management commentary on cell-and-gene-therapy utilization from TMO, DHR, SRT3, and LONN; those data points are more investable than aggregate market-size claims. Over 6-18 months, the upside case requires clinical de-risking and manufacturing utilization to recover simultaneously; a funding slowdown in pre-commercial biotech, FDA CMC setbacks, or Novo's diabetes-cell program failing to advance would undermine the thesis.

Consensus may over-credit platform suppliers for therapeutic enthusiasm while underestimating their exposure to biotech capital budgets. The better relative-value expression is quality scale versus reagent pure plays: large vendors can absorb uneven program funding through adjacent bioprocess and research demand, whereas TECH's multiple is more sensitive to a sustained rebound in academic and emerging-biotech purchasing. NVO has strategic optionality through diabetes cell therapy, but its valuation remains driven by metabolic-drug execution; cell therapy should not yet alter the core earnings thesis.

Key Decisions for Investors

• No directional trade solely on this item; treat it as a monitoring signal. Reassess after the next TMO, DHR, SRT3, and LONN results for cell-and-gene-therapy order growth, book-to-bill, and capacity-utilization disclosure.
• Initiate a 6-12 month relative-value basket: long TMO and LONN / short TECH in equal beta-adjusted dollars. The thesis is that scaled manufacturing and workflow providers capture utilization-led demand with less dependence on early-stage funding; exit if TECH's organic growth exceeds TMO's Life Sciences growth by more than 300 bps for two consecutive quarters or if Lonza guides to lower cell-and-gene capacity utilization.
• Maintain a modest 12-18 month long NVO optionality sleeve only if its diabetes cell-therapy program provides a dated clinical or regulatory catalyst. Size it as a satellite to the obesity/diabetes thesis, not a regenerative-medicine position; reduce if trial updates show immunosuppression, graft durability, or manufacturing constraints that prevent commercially viable patient throughput.
• For GLW, avoid extrapolating a broad stem-cell thesis into earnings until Life Sciences revenue or specialty-vessel commentary confirms incremental demand. A sustained 5%+ organic growth inflection in the relevant labware business would be the required trigger; otherwise the exposure is too diluted to justify a dedicated position.